Abstract

Non-Hodgkin Lymphomas are always treatable and frequently curable malignancies. However, choosing the most appropriate therapy requires accurate diagnosis and a careful staging evaluation. New patients with non-Hodgkin Lymphoma should have their tumors classified using the World Health Organization classification. The specific choice of therapy is dependent on a careful staging evaluation. Patients with non-Hodgkin Lymphoma are assigned an anatomic stage using the Ann Arbor system. However, patients should also be classified using the International Prognostic Index. New insights into the biology of the lymphomas in the coming years might well improve our ability to evaluate patients and choose therapy.

Original languageEnglish (US)
Pages (from-to)368-376
Number of pages9
JournalCa-A Cancer Journal for Clinicians
Volume55
Issue number6
DOIs
StatePublished - Jan 1 2005

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Staging non-Hodgkin lymphoma. / Armitage, James Olen.

In: Ca-A Cancer Journal for Clinicians, Vol. 55, No. 6, 01.01.2005, p. 368-376.

Research output: Contribution to journalReview article

@article{8a216696d10a4963b2c00bbf06b90561,
title = "Staging non-Hodgkin lymphoma",
abstract = "Non-Hodgkin Lymphomas are always treatable and frequently curable malignancies. However, choosing the most appropriate therapy requires accurate diagnosis and a careful staging evaluation. New patients with non-Hodgkin Lymphoma should have their tumors classified using the World Health Organization classification. The specific choice of therapy is dependent on a careful staging evaluation. Patients with non-Hodgkin Lymphoma are assigned an anatomic stage using the Ann Arbor system. However, patients should also be classified using the International Prognostic Index. New insights into the biology of the lymphomas in the coming years might well improve our ability to evaluate patients and choose therapy.",
author = "Armitage, {James Olen}",
year = "2005",
month = "1",
day = "1",
doi = "10.3322/canjclin.55.6.368",
language = "English (US)",
volume = "55",
pages = "368--376",
journal = "CA Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Staging non-Hodgkin lymphoma

AU - Armitage, James Olen

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Non-Hodgkin Lymphomas are always treatable and frequently curable malignancies. However, choosing the most appropriate therapy requires accurate diagnosis and a careful staging evaluation. New patients with non-Hodgkin Lymphoma should have their tumors classified using the World Health Organization classification. The specific choice of therapy is dependent on a careful staging evaluation. Patients with non-Hodgkin Lymphoma are assigned an anatomic stage using the Ann Arbor system. However, patients should also be classified using the International Prognostic Index. New insights into the biology of the lymphomas in the coming years might well improve our ability to evaluate patients and choose therapy.

AB - Non-Hodgkin Lymphomas are always treatable and frequently curable malignancies. However, choosing the most appropriate therapy requires accurate diagnosis and a careful staging evaluation. New patients with non-Hodgkin Lymphoma should have their tumors classified using the World Health Organization classification. The specific choice of therapy is dependent on a careful staging evaluation. Patients with non-Hodgkin Lymphoma are assigned an anatomic stage using the Ann Arbor system. However, patients should also be classified using the International Prognostic Index. New insights into the biology of the lymphomas in the coming years might well improve our ability to evaluate patients and choose therapy.

UR - http://www.scopus.com/inward/record.url?scp=27944455630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944455630&partnerID=8YFLogxK

U2 - 10.3322/canjclin.55.6.368

DO - 10.3322/canjclin.55.6.368

M3 - Review article

C2 - 16282281

AN - SCOPUS:27944455630

VL - 55

SP - 368

EP - 376

JO - CA Cancer Journal for Clinicians

JF - CA Cancer Journal for Clinicians

SN - 0007-9235

IS - 6

ER -